Use of tumor mutational burden as a predictive marker of response to immuno-oncology agents: Initial experience at an academic center in Venezuela
Recommended Citation
Sucre S, Sucre O, Vivas L, Salazar H, Sucre CE. Use of tumor mutational burden as a predictive marker of response to immuno-oncology agents: Initial experience at an academic center in Venezuela. Journal of Clinical Oncology. 2023;41(16_suppl):e14613-e14613. doi:10.1200/JCO.2023.41.16_suppl.e14613
Type
Abstract